Research involving pharmacologic inhibition of histone modification enzyme is of high importance for developing effective therapies for pediatric patients with AT/RT, as recently published results, indicate the abnormal activity of the histone modifier with absence of tumor suppressor gene (SMARCB1) as being of fundamental importance to the occurrence of AT/RTs. By studying how histone modifier regulates gene expressions, by inhibiting the activity in patient-derived AT/RT cells and animal models, with associated genetic (RNA-Sequence) and epigenetic (ChIP-Sequence) analysis, and the results expected to elucidate the molecular basis for histone changes and addiction of histone binding protein (bromodomain protein 4, BRD4) activity on histone modification effect on AT/RT. This information, in turn, will provide insights for testing novel epigenetic therapeutic intervention for treating a currently incurable pediatric brain tumor.
|Effective start/end date||7/1/18 → 6/30/19|
- Rally Foundation, Inc. (Agmt 05/15/18)